Hisamitsu Pharmaceutical Co. Inc. Reports Consolidated and Non-Consolidated Earnings Results for the Third Quarter and Nine Months Ended November 30, 2016; Provides Consolidated and Non-Consolidated Earnings Guidance for the Fiscal Year of 2017
January 12, 2017
Share
Hisamitsu Pharmaceutical Co. Inc. reported consolidated and non-consolidated earnings results for the third quarter and nine months ended November 30, 2016. For the quarter, on consolidated basis the company has posted sales of ¥35,282 million against ¥39,854 million a year ago. Operating profits were ¥9,120 million against ¥8,815 million a year ago. Net profits were ¥9,054 million against ¥5,941 million a year ago. Pre-tax profit was ¥13,219 million against ¥8,840 million a year ago.
For the nine months, on consolidated basis the company has posted sales of ¥109,729 million against ¥122,283 million a year ago. Operating profits were ¥21,995 million against ¥23,324 million a year ago. Net profits were ¥18,340 million against ¥15,318 million a year ago. Pre-tax profit was ¥27,031 million against ¥23,439 million a year ago.
For the quarter, on non-consolidated basis the company has posted sales of ¥27,111 million against ¥29,430 million a year ago. Operating profits were ¥7,602 million against ¥7,453 million a year ago. Net profits were ¥6,010 million against ¥5,158 million a year ago. Pre-tax profit was ¥8,530 million against ¥7,709 million a year ago.
For the nine months, on non-consolidated basis the company has posted sales of ¥83,187 million against ¥90,287 million a year ago. Operating profits were ¥17,887 million against ¥21,187 million a year ago. Net profits were ¥14,145 million against ¥14,605 million a year ago. Pre-tax profit was ¥20,070 million against ¥21,775 million a year ago.
The company provided consolidated and non-consolidated earnings guidance for the fiscal year of 2017. For the year, on consolidated basis the company has expects sales of ¥155,000 million. Operating profits were ¥28,000 million. Net profits were ¥19,400 million. Pre-tax profit was ¥20,070 million.
For the year, on non-consolidated basis the company has expects sales of ¥119,500 million. Operating profits were ¥24,500 million. Net profits were ¥18,000 million. Pre-tax profit was ¥26,800 million.
Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.
Hisamitsu Pharmaceutical Co. Inc. Reports Consolidated and Non-Consolidated Earnings Results for the Third Quarter and Nine Months Ended November 30, 2016; Provides Consolidated and Non-Consolidated Earnings Guidance for the Fiscal Year of 2017